IMMUNOTHERAPY
Latest News
February 6th 2025
This approach aims to improve treatment for patients with this highly aggressive and treatment-resistant type of breast cancer.
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Tennessee
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Kansas
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Nevada
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Missouri
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | New Mexico
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
23rd Annual School of Breast Oncology
November 6-8, 2025
Register Now!
Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments
View More
Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference
View More
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
More News
The Right Drug for the Right Patient: Moving Closer to Truly Personalized Medicine
April 1st 2018It is truly an exciting time in cancer research and drug development and it’s a privilege to be able to join Targeted Therapies in Oncology™ and assist an outstanding team of editors and writers to disseminate the most up-to-date, timely and clinically relevant information in this fast-paced era.
Read More
Higher Toxicity With Checkpoint Inhibitor Treatment Found in Study of Recurrent Ovarian Cancer
March 25th 2018According to study findings presented during the 49th Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers held in New Orleans March 24-27, clinical benefit has been found for women with recurrent ovarian cancer when using immune checkpoint inhibitors, but there was a higher rate of adverse events (AEs) than previously reported in other tumor types.
Read More
Breaking Down the Barriers to Immunotherapy in the Community
March 23rd 2018Although immuno-oncology is increasingly gaining strength within the community setting, familiarity with ever-changing indications, and patient and nonspecialist education are persistent issues for community oncology providers. These are a few of the many barriers currently standing in the way, based on interviews, focus groups, and surveys from 2017.
Read More
Arap and Pasqualini Join Oncology Leadership at Rutgers Cancer Institute of New Jersey
February 21st 2018The Rutgers Cancer Institute of New Jersey has announced 2 new additions to its team of oncology leaders. Wadih Arap, MD, PhD, will serve as the new director of the Rutgers Cancer Institute of New Jersey at University Hospital, and Renata Pasqualini, PhD, will serve as the chief of the Division of Cancer Biology in the Department of Radiation Oncology at Rutgers New Jersey Medical School.
Read More
Jean-Charles Soria to Receive TAT 2018 Honorary Award for Cancer Drug Development
February 20th 2018Jean-Charles Soria, MD, PhD, will be honored with the Targeted Anticancer Therapies 2018 Honorary Award for cancer drug development. Soria has played a large part in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy for the last 15 years.
Read More
